Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies involved in the internet-based first consultation pilot in Beijing. Core Insights - The pilot program for internet-based first consultations in Beijing is expected to have landmark significance for nationwide policy expansion, aiming to relieve offline clinical pressure and extend quality medical resources digitally across China [2][6]. - The policy is anticipated to drive online traffic growth and accelerate prescription outflow, particularly in specialties suitable for remote diagnosis such as dermatology, mental health, and nutrition [7][8]. - The integration of "consultation-examination-diagnosis-medication" services is facilitated by this policy, potentially streamlining patient journeys and reducing transportation costs [8]. Summary by Sections Event - On January 31, 2026, the National Health Commission approved a pilot for internet-based first consultations in pediatric specialties in Beijing, running from January to December 2026 [1][5]. Commentary - The pilot aims to address the medical needs of out-of-town patients and relieve non-capital functions in Beijing, with the potential to serve as a reference for similar initiatives nationwide [2][6]. - If the scope of internet-based first consultations expands, it could lead to significant growth in online consultations and related health product sales [7]. - Leading companies like Alibaba Health and JD Health are expected to benefit from the expansion of this policy [8].

Investment Rating - The report rates multiple companies in the consumer staples sector as "Outperform," including Guizhou Moutai, Wuliangye, and Yili [1]. Core Insights - The consumer staples industry in January 2026 shows a recovery in basic demand while hedonic consumption remains under pressure, indicating a divergence in performance across different segments [3][29]. - Among the eight key consumer industries tracked, four are experiencing positive growth (condiments, frozen food, soft drinks, and catering), while four are facing declines (high-end and above Baijiu, mass-market Baijiu, dairy products, and beer) [29]. Summary by Segment Baijiu (High-end and Above) - In January, the revenue for high-end Baijiu reached 47 billion yuan, a year-on-year decline of 14.0%. The price pressure is significant, with expectations of over a 10% price drop throughout the year due to high inventory levels [11]. Baijiu (Mass-market and Below) - The mass-market Baijiu segment generated 22.9 billion yuan in January, down 3.0% year-on-year. Despite the decline, the segment shows resilience due to rigid demand and adaptability to consumption scenarios [13]. Beer - The beer industry reported revenues of 17 billion yuan in January, a decrease of 7.1% year-on-year. The demand was affected by adverse weather and the delayed Spring Festival, leading to a cautious inventory approach by distributors [15]. Condiments - The condiment sector achieved revenues of 46.9 billion yuan in January, reflecting a year-on-year growth of 3.5%. The recovery in the catering channel and increased demand from small and medium-sized businesses are key drivers [17]. Dairy Products - The dairy sector's revenue was 43.5 billion yuan in January, down 3.3% year-on-year. The demand remains under pressure, but a potential recovery is anticipated in the coming months due to low base effects [19]. Frozen Food - The frozen food segment saw revenues of 14.99 billion yuan in January, with a year-on-year increase of 8%. The demand is supported by pre-Spring Festival stocking and favorable weather conditions [21]. Soft Drinks - The soft drink industry generated 96.2 billion yuan in January, with a modest growth of 1.1% year-on-year. Increased promotional activities indicate heightened market competition [24]. Catering - The catering sector reported revenues of 16.2 billion yuan in January, up 2.5% year-on-year. The demand is gradually improving, particularly in small and medium-sized restaurants [26].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric Appliances, Anta Sports, and many others [1]. Core Insights - The discretionary consumption sector has experienced a significant pullback due to the hawkish stance of the Federal Reserve, leading to a decline in global asset prices [4][13]. - The report highlights that the domestic sportswear sector outperformed other segments, while luxury goods and cosmetics faced notable declines [4][13]. - The report provides a detailed analysis of the performance of various sub-sectors, indicating that gold and jewelry, overseas cosmetics, and snacks have shown resilience compared to the MSCI China index [4][11]. Summary by Relevant Sections Weekly Performance Review - The domestic sportswear sector increased by 0.6%, while other sectors such as credit cards, U.S. hotels, and retail saw declines ranging from -0.4% to -5.8% [4][13]. - The report notes that the gold and jewelry sector has outperformed the MSCI China index, with a monthly increase of 14.8% [4][13]. Sector Analysis - The domestic sportswear sector's growth is attributed to increased demand for warm clothing due to colder weather and positive media coverage of brands like Bosideng [15]. - The credit card sector saw mixed results, with Mastercard rising by 2.7% while Visa and American Express declined [15]. - The retail sector's performance was driven by specific companies like China Resources Mixc Lifestyle, which saw a 10.8% increase due to favorable policies [15]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential investment opportunities [11][18]. - For instance, the expected PE for the domestic sportswear sector is 13.4 times, which is 70% of its past five-year average [18]. Conclusion - Overall, the report emphasizes the impact of macroeconomic factors on the discretionary consumption sector and identifies specific companies and sub-sectors that may present investment opportunities amidst the current market volatility [4][11][18].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the Hong Kong healthcare market experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Highlights - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing an 89% year-on-year increase, and reported a turnaround to profitability [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow and improve access to healthcare services [13].

Investment Focus - The report emphasizes a balanced allocation between technology and value sectors, focusing on market structure rather than short-term index fluctuations [1][11] - Recent market movements show a stronger rebound in value sectors compared to high-tech, with increased expectations for policies supporting the real estate sector [1][12] - Rising commodity prices and stabilization in certain product prices are aiding valuation recovery in undervalued sectors like real estate and baijiu [1][12] Market Outlook - The report anticipates stabilization and upward movement in Chinese equities (A-shares and Hong Kong stocks) leading into the Lunar New Year, driven by domestic fundamentals and liquidity conditions [2][13] - A series of political and economic catalysts, including local and national meetings and the rollout of the 15th Five-Year Plan, are expected to enhance market sentiment [2][13] Investment Strategy - The report suggests positioning for the Lunar New Year "red packet" rally by focusing on industries benefiting from holiday effects and macroeconomic catalysts [2][14] - Key areas of focus include AI applications, high-quality tech manufacturing, and future industries such as defense and domestic chip production [2][14] Sector Analysis - Non-bank financials, particularly brokers and insurers, are expected to recover from previous outflows due to their strong fundamentals [3][19] - The holiday consumption chain, including sectors like gaming, food and beverage, and travel, is highlighted as a potential growth area [3][19] - Hong Kong dividend assets with earnings leverage, such as real estate and chemicals, are also noted for their potential upside following policy support [3][19] Liquidity Data - A-share ETF flows show a divergence, with broad-based ETFs experiencing significant outflows while sector-specific ETFs saw inflows, particularly in metals and chemicals [4][16] - In Hong Kong, short-selling activity has returned to historical averages, with notable inflows into energy and property sectors [5][17]

[Table_Title] 研究报告 Research Report 1 Feb 2026 中国策略 China Strategy 海通国际 2026 年 2 月金股 HTI February 2026 Top Picks 周林泓 Amber Zhou amber.lh.zhou@htisec.com 2 Feb 2026 3 [Table_yemei1] 观点聚焦 Investment Focus | 行业组 | 分析师 | 行业 | Top Pick | 看好理由 | | --- | --- | --- | --- | --- | | | | | | Google 被 AI 搜索压制的估值已经在逐步释放：1）通过 AI Overview | | | | | | 过渡 + AI mode 解锁交互式 AI 搜索功能，守护搜索市场，未来广告 | | | | | | 业务保持良好能见度；2）Google TPU 订单激增，Meta OpenAI 等大 | | | | | Alphabet (GOOGL US) | 量订购 TPU V7 系列。预计云业务全年 30%+增速，并且通过规模效 | | | | | | ...

[Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment 孟科含 Kehan Meng 聂照亿 Zhaoyi Nie 3）双方还将依托该等平台就另外四个新增项目开展合作。 kh.meng@htisec.com john.zy.nie@htisec.com 交易对价 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康 ...

Investment Rating - The report provides various investment ratings for companies in the consumer staples sector, with several companies rated as "Outperform" and one as "Neutral" [1]. Core Insights - The report indicates that price hikes in the consumer staples sector are weaker than expected, while costs remain low [1]. - The monitored spot cost indices for six consumer goods categories have declined, while futures cost indices have primarily increased [34]. Summary by Category Beer - The spot cost index decreased by 1.87% month-on-month, while the futures index increased by 3.15%. Year-to-date, the spot index has changed by -0.6% and the futures index by +1.81% [35]. - Glass prices have shown a month-on-month decrease of 1.2% for spot prices and an increase of 3.4% for futures prices [35]. Condiments - The spot cost index decreased by 1.37% month-on-month, while the futures index increased by 3.03%. Year-to-date changes are -0.42% for spot and +2.23% for futures [36]. - Soybean prices have decreased by 2.4% month-on-month for spot prices, while futures prices increased by 6.7% [36]. Dairy Products - The spot cost index decreased by 1.93% month-on-month, while the futures index increased by 1.58%. Year-to-date changes are -0.43% for spot and +1.68% for futures [37]. - Fresh milk prices rose to 3.04 yuan/kg, with corn prices increasing by 0.4% month-on-month [37]. Instant Noodles - The spot cost index decreased by 0.51% month-on-month, while the futures index increased by 3.31%. Year-to-date changes are +0.79% for spot and +3.46% for futures [38]. - Palm oil prices increased by 9.6% month-on-month for spot prices [38]. Frozen Food - The spot cost index decreased by 1.74% month-on-month, while the futures index decreased by 0.61%. Year-to-date changes are -1.44% for spot and -0.14% for futures [39]. - Vegetable prices fell by 1.8% month-on-month [39]. Soft Drinks - The spot cost index decreased by 3.71% month-on-month, while the futures index remained unchanged. Year-to-date changes are -1.12% for spot and -0.19% for futures [40]. - PET chip prices increased by 5.4% month-on-month [40].

Investment Rating - The report maintains an "Outperform" rating for Sands China [2][16]. Core Insights - The company achieved net revenue of USD 2.058 billion in Q4 2025, representing a year-over-year increase of 16.2%. Adjusted property EBITDA reached USD 608 million, up 6.5% year-over-year, with an adjusted property EBITDA margin of 29.5% [4][12]. - The performance of the company's properties varied, with The Venetian and Plaza showing net revenue increases both year-over-year and quarter-over-quarter, while The Parisian and Sands underperformed [13][14]. - The company's gaming gross revenue increased significantly to USD 2.02 billion, up 23.1% year-over-year, driven by growth in VIP and premium mass segments [5][14]. - The adjusted EBITDA margin declined to 29.5%, down 2.7 percentage points year-over-year, primarily due to a shift in business structure and rising operating costs [6][15]. - The company's market share improved to 24.4% in Q3 2025, up from 23.7% in Q3 2024, indicating a positive trend in competitive positioning [7]. Financial Projections - For FY 2026 and 2027, net revenue is projected to be USD 7.937 billion and USD 8.363 billion, respectively, with gaming gross revenue expected to reach USD 7.652 billion and USD 8.082 billion [16]. - The adjusted property EBITDA is forecasted to be USD 2.483 billion in 2026 and USD 2.643 billion in 2027, with corresponding adjusted property EBITDA margins of 31.3% and 31.6% [16].

研究报告 Research Report 29 Jan 2026 新东方-S New Oriental (9901 HK) 超预期并上调指引；降本增效战略持续显效 Beat and Raise guidance; efficiency improvement strategy is yielding results [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$46.04 目标价 HK$52.00 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$75.29bn / US$9.65bn 日交易额 (3 个月均值) US$19.47mn 发行股票数目 1,635mn 自由流通股 (%) 88% 1 年股价最高最低值 HK$47.24-HK$32.85 注：现价 HK$46.04 为 2026 年 01 月 29 日收盘价 资料来源： F ...